 |
 |
 |
|
Systematic Literature Review of Real-world Experience With the 2-Drug Regimen Dolutegravir and Lamivudine
in People With HIV Who Would Not Have Met Inclusion Criteria for the Phase 3 Clinical Program
|
|
|
IDWeek 2022; October 19-23, 2022; Virtual and Washington, DC
Jihad Slim,1 Douglas Ward,2 Stefan Schneider,3 Madhusudan Kabra,4 Gustavo Verdier,5 Bryn Jones,4 Emilio Letang6
1Saint Michael’s Medical Center, Newark, NJ, USA; 2Dupont Circle Physicians Group, Washington, DC, USA; 3Long Beach Education and Research Consultants, Long Beach, CA, USA; 4ViiV Healthcare, Brentford, UK; 5ViiV Healthcare, Montréal, QC, Canada; 6ViiV Healthcare, Madrid, Spain




|
|
|
 |
 |
|
|